1.580USD+0.64%Mkt Cap: —P/E: —1d ago
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value804.28M $
Revenue (TTM)204.56M $
Gross Profit119.67M $
Net Income (TTM)-67.61M $
Revenue/Share0.3060 USD
Last Price1.580 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees258
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS3741631036
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-23.11
EV/Revenue3.93
P/S—
P/B4.47
EPS (TTM)-0.36
EPS (Forward)—
52W Range
1.49090% of range1.590
52W High1.590 USD
52W Low1.490 USD
Profitability
Gross Margin58.50%
Oper. Margin-22.01%
EBITDA Margin-17.01%
Profit Margin-33.05%
ROE-28.28%
ROA-4.11%
Growth
Revenue Growth17.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-114.38M $
CapEx (TTM)—
FCF Margin-38.31%
FCF Yield—
Net Debt-178.70M $
Net Debt/EBITDA5.14
Balance Sheet
Debt/Equity55.87
Current Ratio6.92
Quick Ratio5.04
Book Value/Sh0.3400 USD
Cash/Share0.4680 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.186.35M
Float556.32M
Insiders0.08%
Institutions76.44%
Technical
SMA 502.075 (-23.8%)
SMA 2002.451 (-35.5%)
Beta0.59
S&P 52W Chg20.80%
Avg Vol (30d)12.83K
Avg Vol (10d)44.71K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—